Influence of oil droplet surface charge on the performance of antibody--emulsion conjugates.

Targeted drug delivery requires binding of (and subsequent uptake by) the carrier to target cells. The purpose of our present study is to compare the binding and uptake of emulsions with different electric surface properties to SK-BR3 cell line, which over-expresses the HER2 receptor. Cationic emulsion was prepared by incorporating 0.25% w/w of the cationic lipid, stearylamine in the formulation while the anionic emulsion formulation was identical but lacking stearylamine. Immunoemulsions were prepared by conjugating the 2-iminothiolane derivative of the monoclonal antibody trastuzumab (Herceptin) through the reactive maleimide group of the octadecyl-4-(maleimidomethyl)cyclohexane-carboxylic amide linker which was incorporated in the oil phase of the anionic and cationic emulsions. Cationic emulsion exhibited a droplet size of approximately 130 nm and a zeta potential of +50 mV compared to anionic emulsion with a droplet size of approximately 140 nm and a zeta potential of -30 mV which decreased to -5 mV following antibody coupling. There was no significant difference in the coupling efficiency of trastuzumab to anionic and cationic emulsions which was in the range of 60-70%. The cationic emulsion and immunoemulsion appeared to be physically stable over a long period of time, as indicated by particle-size measurements while the droplets of the anionic immunoemulsion coalesced with time resulting in phase separation within 20 days storage at 4 degrees C. The results of binding and uptake to cells showed that both cationic and anionic immunoemulsions bind and internalized to cells much more than the respective blank emulsions. The enhanced penetration of the probe coumarin-6 with both immunoemulsions clearly indicated that the internalization process was mainly controlled by a cell-receptor endocytosis mechanism mediated by the binding affinity of trastuzumab to the cell surface receptor since the uptake of the cationic immunoemulsion was not significantly different from the uptake of the anionic immunoemulsion. However, only the cationic immunoemulsion might be considered for further investigation in view of its long standing physical stability.

[1]  R. Müller,et al.  In vitro adsorption of plasma proteins onto the surface (charges) modified-submicron emulsions for intravenous administration. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[2]  T. Allen,et al.  Ligand-targeted liposomes for cancer treatment. , 2005, Current drug delivery.

[3]  M. Bally,et al.  The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations. , 2005, Current drug delivery.

[4]  T. Allen,et al.  A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. , 1995, Biochimica et biophysica acta.

[5]  U. Zangemeister‐Wittke Antibodies for Targeted Cancer Therapy – Technical Aspects and Clinical Perspectives , 2006, Pathobiology.

[6]  E. Papadimitriou,et al.  Interactions of PC/Chol and PS/Chol Liposomes with Human Cells in Vitro , 2000, Journal of drug targeting.

[7]  T M Allen,et al.  In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. , 1998, Cancer research.

[8]  G. Griffiths,et al.  Cellular association and cytotoxicity of anti-CD74-targeted lipid drug-carriers in B lymphoma cells. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[9]  M. Yokoyama,et al.  Drug targeting with nano-sized carrier systems , 2005, Journal of Artificial Organs.

[10]  Y K Song,et al.  Antibody mediated lung targeting of long-circulating emulsions. , 1996, PDA journal of pharmaceutical science and technology.

[11]  G. Griffiths,et al.  Conjugation of an Anti‐B‐cell Lymphoma Monoclonal Antibody, LL2, to Long‐circulating Drug‐carrier Lipid Emulsions , 1999, The Journal of pharmacy and pharmacology.

[12]  S. Benita,et al.  The design and evaluation of a novel targeted drug delivery system using cationic emulsion-antibody conjugates. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[13]  T. Allen,et al.  Ligand-targeted liposomal anticancer drugs. , 2003, Progress in lipid research.

[14]  V. Schirrmacher,et al.  Tumour targeting with antibody-coupled liposomes: Failure to achieve accumulation in xenografts and spontaneous liver metastases , 1990, Cancer Immunology, Immunotherapy.

[15]  I. Ahmad,et al.  Antibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitro. , 1992, Cancer research.

[16]  Fumiyoshi Yamashita,et al.  Lipid carrier systems for targeted drug and gene delivery. , 2005, Chemical & pharmaceutical bulletin.

[17]  D. Papahadjopoulos,et al.  Quantitative analysis of liposome-cell interactions in vitro: rate constants of binding and endocytosis with suspension and adherent J774 cells and human monocytes. , 1993, Biochemistry.

[18]  S. Benita,et al.  Enhanced absorption and drug targeting by positively charged submicron emulsions , 2000 .

[19]  V. Torchilin Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.